In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endoge...

The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds

The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II) where the carbon atom designated * is in the R or S configuration and the substituents X and R-Rare as defined herein.

A compound of formulae I(A-E) having the following structure: R5* R 4 N I(A-E) wherein: the carbon atom designated * is in the R or S configuration; X is phenyl optionally substituted from 1 to 4 times with substituents as defined in R1 4 ; R' is H methyl ethyl or isopropyl; R2 is H methyl or gem-dimethyl; R3 is H methyl hydroxy methoxy fluoro chloro cyano trifluoromethyl or trifluoromethoxy; R4 is pyrimidinyl optionally substituted from 1 to 4 times with substituents as defined below in R5 is H...

Methods, compositions, systems, and packaging are disclosed for reducing postoperative nausea and/or vomiting (PONV) in a human patient in need of general anesthesia for surgery. Such methods may include scheduling a surgery for the human patient, and administering to the patient one or more series of prescribed medicines for at least three successive days during a regimen immediately preceding general anesthesia. Compositions may include cholinergic receptor agonists, muscarinic receptor agonis...

597433 Disclosed herein is are 3-phenoxymethylpyrrolidine compounds of formula (I), wherein the substituents are as defined within the specification, examples being (S)-3-[ 1-(2,3,6-trichlorophenoxy)prop-2-ynyl]pyrrolidine and (S)-3 -[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. Processes for their preparation, compositions comprising said compounds and uses thereof are also disclosed. Said compounds have useful activity as serotonin (5-HT) and norepinephrine (NE) reuptake inhibitors and ...